JP2016530239A - 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 - Google Patents

微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 Download PDF

Info

Publication number
JP2016530239A
JP2016530239A JP2016525434A JP2016525434A JP2016530239A JP 2016530239 A JP2016530239 A JP 2016530239A JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016525434 A JP2016525434 A JP 2016525434A JP 2016530239 A JP2016530239 A JP 2016530239A
Authority
JP
Japan
Prior art keywords
composition
clostridium cluster
clostridium
butyrate
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016525434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016530239A5 (https=
Inventor
賢也 本田
賢也 本田
オーレ、バーナット
幸二 新
幸二 新
大 田之上
大 田之上
大野　博司
博司 大野
真嗣 福田
真嗣 福田
耕二 長谷
耕二 長谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Publication of JP2016530239A publication Critical patent/JP2016530239A/ja
Publication of JP2016530239A5 publication Critical patent/JP2016530239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
JP2016525434A 2013-07-09 2014-07-08 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物 Pending JP2016530239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844204P 2013-07-09 2013-07-09
US61/844,204 2013-07-09
PCT/US2014/045801 WO2015006355A2 (en) 2013-07-09 2014-07-08 Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019092447A Division JP2019189609A (ja) 2013-07-09 2019-05-15 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物

Publications (2)

Publication Number Publication Date
JP2016530239A true JP2016530239A (ja) 2016-09-29
JP2016530239A5 JP2016530239A5 (https=) 2017-08-17

Family

ID=52280706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016525434A Pending JP2016530239A (ja) 2013-07-09 2014-07-08 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
JP2019092447A Pending JP2019189609A (ja) 2013-07-09 2019-05-15 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019092447A Pending JP2019189609A (ja) 2013-07-09 2019-05-15 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物

Country Status (4)

Country Link
US (3) US9764019B2 (https=)
EP (1) EP3019181A4 (https=)
JP (2) JP2016530239A (https=)
WO (1) WO2015006355A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505471A (ja) * 2017-01-27 2020-02-20 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
WO2020071463A1 (ja) * 2018-10-04 2020-04-09 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
CN110996933A (zh) * 2017-07-13 2020-04-10 H·普兹内泰克 用于帕金森病的预防性和/或支持性治疗处理的药剂
JP2022541528A (ja) * 2019-07-17 2022-09-26 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション クロストリジウム綱コンソーシアムの組成ならびに肥満、メタボリックシンドローム及び過敏性腸疾患の治療法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
PH12013500224A1 (en) 2010-08-04 2013-04-08 Borody Thomas J Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
MX2013010343A (es) 2011-03-09 2014-04-30 Univ Minnesota Composicion y metodos para el transplante de microbiota de colon.
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN116942833A (zh) 2011-12-01 2023-10-27 国立大学法人 东京大学 诱导调节性t细胞的增殖或积累的人源细菌
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
CN105916500A (zh) 2013-11-27 2016-08-31 欧洲筛选有限公司 用于治疗炎性疾病的化合物、药物组合物和方法
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
WO2016102950A1 (en) 2014-12-23 2016-06-30 4D Pharma Research Limited Immune modulation
SG11201704814SA (en) 2014-12-23 2017-07-28 4D Pharma Res Ltd Pirin polypeptide and immune modulation
CN107405321A (zh) 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
AU2016268158B2 (en) 2015-05-22 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
ME03511B (me) 2015-06-15 2020-04-20 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
WO2016203221A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HRP20191949T1 (hr) 2015-06-15 2020-01-24 4D Pharma Research Limited Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SG10201913557TA (en) 2016-03-04 2020-02-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
CA3211208A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2018187464A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
EP3612570A4 (en) 2017-04-17 2021-01-13 The University of Chicago POLYMERIC MATERIALS FOR THE ADMINISTRATION OF SHORT-CHAIN FATTY ACIDS TO THE INTESTINE FOR HUMAN HEALTH AND DISEASE TREATMENT APPLICATIONS
ES2877726T3 (es) 2017-05-22 2021-11-17 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
JP2020521760A (ja) 2017-05-26 2020-07-27 クレストヴォ・ホールディングス・エルエルシー 糞便微生物ベースの治療剤を含む凍結乾燥組成物ならびにそれを製造および使用する方法
TWI812624B (zh) 2017-06-14 2023-08-21 南韓商希杰生物科技股份有限公司 包含細菌品系之組成物
ES2841902T3 (es) 2017-06-14 2021-07-12 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
WO2019032573A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER
WO2019152344A1 (en) * 2018-01-30 2019-08-08 University Of Louisville Research Foundation, Inc. Compositions and methods for treating inflammation and cancer
AU2019282691A1 (en) 2018-06-05 2020-12-24 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
WO2020037271A1 (en) 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
US11911419B2 (en) 2018-09-27 2024-02-27 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
EP4034096B1 (en) * 2019-09-25 2025-12-31 Philipps-Universität Marburg SHORT-CHAIN FATTY ACID PENTANOATE AS AN ACTIVATOR FOR CELL THERAPY AND ANTITUMOR THERAPY
US12397563B2 (en) 2023-08-24 2025-08-26 Stolle Machinery Company, Llc Automatic label creator and method for can decorating

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2383662A1 (fr) * 1977-03-15 1978-10-13 Cassenne Lab Sa Nouvelles compositions a usage cosmetique
DE3068965D1 (en) * 1979-11-16 1984-09-20 Sterosynt Ltd 6-alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
US5569680A (en) * 1995-02-13 1996-10-29 Trustees Of The Univ. Of Penna Method of treating inflammatory bowel disease with tributyrin
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
WO2002080963A1 (en) * 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
EP1743654A1 (en) 2005-07-15 2007-01-17 TopoTarget Germany AG Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
GB0903016D0 (en) 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＳＣＩＥＮＣＥ, vol. [online], JPN6018011895, 4 July 2013 (2013-07-04), pages 10 - 1126, ISSN: 0004101884 *
ＳＣＩＥＮＣＥ, vol. 331, no. 6015, JPN6018011894, 2011, pages 337 - 341, ISSN: 0004101883 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020505471A (ja) * 2017-01-27 2020-02-20 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
JP7161731B2 (ja) 2017-01-27 2022-10-27 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
JP2022179617A (ja) * 2017-01-27 2022-12-02 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
JP7688360B2 (ja) 2017-01-27 2025-06-04 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
CN110996933A (zh) * 2017-07-13 2020-04-10 H·普兹内泰克 用于帕金森病的预防性和/或支持性治疗处理的药剂
JP2020526485A (ja) * 2017-07-13 2020-08-31 ホルスト プルツンテクＨｏｒｓｔ Ｐｒｚｕｎｔｅｋ パーキンソン病の予防および／または支持治療処置のための物質
JP7206223B2 (ja) 2017-07-13 2023-01-17 プルツンテク ホルスト パーキンソン病の予防および／または支持治療処置のための物質
WO2020071463A1 (ja) * 2018-10-04 2020-04-09 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
JPWO2020071463A1 (ja) * 2018-10-04 2021-09-16 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
JP7444459B2 (ja) 2018-10-04 2024-03-06 国立研究開発法人理化学研究所 ＩＬＣ２を標的としたＩｇＡ産生誘導方法
JP2022541528A (ja) * 2019-07-17 2022-09-26 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション クロストリジウム綱コンソーシアムの組成ならびに肥満、メタボリックシンドローム及び過敏性腸疾患の治療法
JP7677640B2 (ja) 2019-07-17 2025-05-15 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション クロストリジウム綱コンソーシアムの組成ならびに肥満、メタボリックシンドローム及び過敏性腸疾患の治療法

Also Published As

Publication number Publication date
WO2015006355A3 (en) 2015-11-26
US9764019B2 (en) 2017-09-19
US20180000921A1 (en) 2018-01-04
US20160144014A1 (en) 2016-05-26
WO2015006355A8 (en) 2016-03-31
US20190134179A1 (en) 2019-05-09
JP2019189609A (ja) 2019-10-31
WO2015006355A2 (en) 2015-01-15
EP3019181A2 (en) 2016-05-18
US10130695B2 (en) 2018-11-20
EP3019181A4 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
JP2019189609A (ja) 微生物叢由来生物活性分子の組み合わせを含む疾患治療用組成物
US10548844B2 (en) pH-responsive mucoadhesive polymeric encapsulated microorganisms
Song et al. In situ bioorthogonal conjugation of delivered bacteria with gut inhabitants for enhancing probiotics colonization
JP6464142B2 (ja) プロバイオティクス生物及び／又は治療剤の標的化胃腸管デリバリー
KR101902035B1 (ko) 산성 분해로부터 미생물 세포의 보호
JP2020530494A (ja) 健康な腸バリアを維持及び回復するための組成物及び方法
US12144834B2 (en) Methods and compositions for treating gastrointestinal and inflammatory disorders
WO1999064023A1 (en) Lactic acid bacterium-containing compositions, drugs and foods
FR2962045A1 (fr) Complexe macromoleculaire d'origine bacterienne et utilisation dudit complexe moleculaire pour prevenir et traiter les rhumatismes inflammatoires
TW202003834A (zh) 用於誘導cd8+t細胞的組成物及方法
Štofilová et al. Cytokine production in vitro and in rat model of colitis in response to Lactobacillus plantarum LS/07
Bosch et al. Development of a time-dependent oral colon delivery system of anaerobic Odoribacter splanchnicus for bacteriotherapy
CA3052975A1 (en) Compositions and methods for treating disease associated with permeability of intestinal epithelium
Bansal et al. Probiotics: from functional foods to pharmaceutical products
WO2024035781A1 (en) Mucoadhesive probiotic backpacks with ros nano-scavengers enhance the bacteriotherapy for inflammatory bowel diseases
WO2022236365A1 (en) Compositions and methods for treating disease
JP2007533755A (ja) 高分子量ｐｅｇ様化合物を含む治療薬送達システム
US11090357B2 (en) Bioengineered lactobacillus probiotics and the uses thereof
Liu et al. Intestinal bacteria encapsulated by biomaterials enhance immunotherapy
CN115916235A (zh) 包含d-氨基酸的拉瑞唑来衍生物
Vasudevan et al. Beta-glucan as a potent growth enhancer for autochthonous gut isolate Ligilactobacillus salivarius C57
US20260027161A1 (en) Bacterial strains for treating disease
US20250268953A1 (en) Compositions and methods for treating disease ii
Tian et al. Engineered strategies for the allergic disease therapy
Cotta et al. Evaluation of the intestinal colonizing potential and immunomodulating capacity of lactobacilli microspheres

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170705

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20171011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190515

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190515

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190709

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190716

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190823

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190827

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200407

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200512

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200707

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20201013

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20201110

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20201110